Search Results
147 results found-
Here’s why thousands of biotech leaders flock to the global meetup
https://www.csl.com/we-are-csl/vita-original-stories/2019/2019-bio-international-convention-philadelphia -
Seqirus operates state-of-the-art revenue with substantial markets in Asia production facilities in the United States (US), the Pacific, Europe and North America.
https://www.csl.com/-/media/csl/tax-transparency-reports/csl-limited-tax-transparency-report-2019.pdf -
CSL Behring is a global leader in developing and delivering high-quality medicines that treat people with rare and serious diseases.
https://www.csl.com/we-are-csl/our-businesses-and-products/csl-behring/csl-behring-products -
CSL Behring A new state of the art recombinant coagulation CSL's operations in Switzerland primarily facility is being constructed at Lengnau.
https://www.csl.com/-/media/csl/tax-transparency-reports/csl-limited-tax-transparency-report-2018.pdf -
For å fastslå en passende oppbevaringsperiode for personopplysninger vurderer vi mengde, art og sensitivitet knyttet til personopplysningene, den potensielle risikoen for skade ved uautorisert bruk eller videreformidling av personopplysningene, formålene vi behandler personopplysningene til, hvorvidt vi kan oppfylle disse formålene på andre måter samt gjeldende lovkrav.
https://www.csl.com/-/media/shared/documents/adverse-event-reporting-privacy-notice-languages/suspected-adverse-event-reportingprivacy-notice_no.pdf -
Seqirus operates state-of-the-art prevent haemolytic disease in newborns, production facilities in the US, the for urgent warfarin reversal in patients CSL Plasma, a division of CSL Behring, United Kingdom (UK) and Australia and with acute major bleeding, to prevent operates one of the world's largest utilises both egg-based and cell-based infection in solid organ transplant and most efficient plasma collection manufacturing technologies as well as a recipients and treat specific infections, networks, with more than 200 centres proprietary adjuvant.
https://www.csl.com/-/media/csl/documents/annual-report-docs/csl-ltd-annual-report-2018-full.pdf -
To report an undesirable effect or adverse event, please contact CSL Behring today.
https://www.csl.com/contact/report-a-behring-undesirable-effect -
com.au specialty.com.au products, and specialty products that are shifting Seqirus operates state-of-the-art production haemophilia and coagulation therapies and treatment paradigms around the world, CSL facilities in the US, the United Kingdom (UK) breakthrough medicines.
https://www.csl.com/-/media/csl/corporate-responsibility-reports/csl-limited-corporate-responsibility-report-2017.pdf -
With an integrated manufacturing Seqirus operates state-of-the-art production medicines are purified from human plasma.
https://www.csl.com/-/media/csl/documents/annual-report-docs/csl-ltd-annual-report-2016-full.pdf -
Plasma collection centres across Europe and North America From our emerging family of recombinant coagulation products that aim to dramatically improve the lives of patients with bleeding disorders, to industry-leading immunoglobulin CSL Plasma, a division of CSL Behring, Seqirus operates state-of-the-art production RESEARCH AND DEVELOPMENT operates one of the world's largest and most facilities in the US, the United Kingdom (UK) and specialty products that are shifting CSL continues to grow investment in the efficient plasma collection networks with and Australia, utilises both egg-based and treatment paradigms around the world, development of protein-based medicines to more than 170 centres in the United States cell-based manufacturing technologies and CSL Behring knows how to meet the needs of treat serious human illnesses.
https://www.csl.com/-/media/csl/documents/annual-report-docs/csl-ltd-annual-report-2017-full.pdf